Efficacy and Safety of Oxaliplatin Combined With Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Colon Cancer Patients

Inclusion Criteria: 1. Performance status (ECOG) 0\~2 2. Histologically confirmed colon cancer. 3. No prior treatment 4. CT-defined T4 or lymph node-positive colon cancer 5. Neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, and hemoglobin ≥ 8 g/dL Bilirubin level ≤ 1.0 x ULN 6. AST and ALT \< 1.5 x ULN 7. Serum creatinine ≤ 1.0 x ULN 8. Life expectancy of ≥ 3 months 9. Signed written informed consent Exclusion Criteria: 1. Final stage with cancer cachexia 2. Allergy for capecitabine or oxaliplatin 3. Any evidence of extrahepatic metastases and/or primary tumor recurrence 4. Severe organ failures or diseases, including: clinically relevant coronary disease, cardiovascular disorder or myocardial infarction within 12 months before study entry, severe psychiatric illness, severe infection and DIC